Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Mol Cell Proteomics. 2013 May;12(5):1204-13. doi: 10.1074/mcp.M112.025858. Epub 2013 Jan 28.
Mutation and overexpression of receptor tyrosine kinases or the proteins they regulate serve as oncogenic drivers in diverse cancers. To better understand receptor tyrosine kinase signaling and its link to oncogenesis, we used protein microarrays to systematically and quantitatively measure interactions between virtually every SH2 or PTB domain encoded in the human genome and all known sites of tyrosine phosphorylation on 40 receptor tyrosine kinases and on most of the SH2 and PTB domain-containing adaptor proteins. We found that adaptor proteins, like RTKs, have many high affinity bindings sites for other adaptor proteins. In addition, proteins that drive cancer, including both receptors and adaptor proteins, tend to be much more highly interconnected via networks of SH2 and PTB domain-mediated interactions than nononcogenic proteins. Our results suggest that network topological properties such as connectivity can be used to prioritize new drug targets in this well-studied family of signaling proteins.
受体酪氨酸激酶或其调控蛋白的突变和过表达在多种癌症中充当致癌驱动因素。为了更好地理解受体酪氨酸激酶信号及其与致癌作用的关系,我们使用蛋白质微阵列系统地和定量地测量了人类基因组中编码的几乎每个 SH2 或 PTB 结构域与 40 个受体酪氨酸激酶上所有已知酪氨酸磷酸化位点以及大多数含有 SH2 和 PTB 结构域的衔接蛋白上的酪氨酸磷酸化位点之间的相互作用。我们发现,衔接蛋白与 RTKs 一样,具有许多高亲和力的结合位点,可与其他衔接蛋白结合。此外,驱动癌症的蛋白质,包括受体和衔接蛋白,通过 SH2 和 PTB 结构域介导的相互作用形成的网络,比非致癌蛋白的相互作用更加紧密。我们的结果表明,网络拓扑性质(如连通性)可用于优先考虑这个研究充分的信号蛋白家族中的新药物靶点。